Abstract
We show that a previously described Klebsiella pneumoniae variant that is resistant to ceftazidime-avibactam plus meropenem-vaborbactam, has a ramR plus ompK36 mutation, and produces the V239G variant KPC-3 (V240G per the standard numbering system) exhibits resistance to ceftazidime-avibactam plus aztreonam and imipenem-relebactam but not cefepime-taniborbactam. The V239G variant does not generate collateral β-lactam susceptibility like many KPC-3 variants associated with ceftazidime-avibactam resistance. Additional mutation of ompK35 and production of the OXA-48-like carbapenemase OXA-232 were required to confer cefepime-taniborbactam resistance.
Keywords:
KPC; carbapenemase.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Bacterial Agents / pharmacology
-
Azabicyclo Compounds / pharmacology
-
Aztreonam* / pharmacology
-
Bacterial Proteins / genetics
-
Borinic Acids
-
Boronic Acids
-
Carboxylic Acids
-
Cefepime / pharmacology
-
Ceftazidime / pharmacology
-
Drug Combinations
-
Imipenem / pharmacology
-
Klebsiella pneumoniae* / genetics
-
Meropenem / pharmacology
-
Microbial Sensitivity Tests
-
beta-Lactamases / genetics
Substances
-
Anti-Bacterial Agents
-
Azabicyclo Compounds
-
Bacterial Proteins
-
Borinic Acids
-
Boronic Acids
-
Carboxylic Acids
-
Drug Combinations
-
avibactam, ceftazidime drug combination
-
vaborbactam
-
Imipenem
-
Cefepime
-
taniborbactam
-
Ceftazidime
-
beta-Lactamases
-
Meropenem
-
Aztreonam
-
relebactam